Brand Name(s):Targaxan 550mg tab
Indication: Hepatic encephalopathy
Rifamixin is licensed for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients aged 18 years or older. NICE guidance is based on 6-month trial data. A secondary care review will be undertaken at a maximum of six months following initiation. Continuation will be decided based on clinical efficacy.
The recommended dose is 550mg twice daily. The 200mg tablet (unlicensed) should not be prescribed.
Rifaximin (Targaxan) is recommended for preventing episodes of hepatic encephalopathy in people aged 18 years or older. Full information can be found at:http://www.nice.org.uk/guidance/ta337/resources/guidance-rifaximin-for-preventing-episodes-of-overt-hepatic-encephalopathy-pdf